Switch theme
Sign up to access all valuation multiples
Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on. The company operates both a third-party B2C service, or 3P, and its own direct-to-consumer business, or 1P, with its own inventory, which can both be accessed by Alibaba’s Tmall app and Alipay. The company also provides online consultation services in a separate app called Yilu or “Dr. Deer,” although its e-commerce businesses remain its core competency in the long-term. E-commerce accounted for 93% of revenue in fiscal year 2022. We estimate that AliHealth holds about 45% of market share in the industry in terms of GMV. AliHealth is 63.74% owned by its parent company, Alibaba Group.
1998
1.4K+
LTM Revenue $4.7B
LTM EBITDA $248M
$8.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alibaba Health has a last 12-month revenue (LTM) of $4.7B and a last 12-month EBITDA of $248M.
In the most recent fiscal year, Alibaba Health achieved revenue of $3.4B and an EBITDA of $128M.
Alibaba Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alibaba Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.7B | XXX | $3.4B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $752M | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBITDA | $248M | XXX | $128M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $251M | XXX | $91.6M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $235M | XXX | $113M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alibaba Health's stock price is HKD 5 (or $1).
Alibaba Health has current market cap of HKD 72.9B (or $9.3B), and EV of HKD 64.1B (or $8.2B).
See Alibaba Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.2B | $9.3B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alibaba Health has market cap of $9.3B and EV of $8.2B.
Alibaba Health's trades at 2.4x EV/Revenue multiple, and 70.9x EV/EBITDA.
Equity research analysts estimate Alibaba Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alibaba Health has a P/E ratio of 43.0x.
See valuation multiples for Alibaba Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.3B | XXX | $9.3B | XXX | XXX | XXX |
| EV (current) | $8.2B | XXX | $8.2B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 36.0x | XXX | 70.9x | XXX | XXX | XXX |
| EV/EBIT | 35.5x | XXX | 116.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 43.0x | XXX | 91.6x | XXX | XXX | XXX |
| EV/FCF | 46.5x | XXX | 75.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlibaba Health's last 12 month revenue growth is 9%
Alibaba Health's revenue per employee in the last FY averaged $2.4M, while opex per employee averaged $0.5M for the same period.
Alibaba Health's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alibaba Health's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alibaba Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | 72% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alibaba Health acquired XXX companies to date.
Last acquisition by Alibaba Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Alibaba Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alibaba Health founded? | Alibaba Health was founded in 1998. |
| Where is Alibaba Health headquartered? | Alibaba Health is headquartered in Hong Kong. |
| How many employees does Alibaba Health have? | As of today, Alibaba Health has 1.4K+ employees. |
| Who is the CEO of Alibaba Health? | Alibaba Health's CEO is Mr. Difan Shen. |
| Is Alibaba Health publicy listed? | Yes, Alibaba Health is a public company listed on HKG. |
| What is the stock symbol of Alibaba Health? | Alibaba Health trades under 00241 ticker. |
| When did Alibaba Health go public? | Alibaba Health went public in 1972. |
| Who are competitors of Alibaba Health? | Similar companies to Alibaba Health include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Alibaba Health? | Alibaba Health's current market cap is $9.3B |
| What is the current revenue of Alibaba Health? | Alibaba Health's last 12 months revenue is $4.7B. |
| What is the current revenue growth of Alibaba Health? | Alibaba Health revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Alibaba Health? | Current revenue multiple of Alibaba Health is 1.9x. |
| Is Alibaba Health profitable? | Yes, Alibaba Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alibaba Health? | Alibaba Health's last 12 months EBITDA is $248M. |
| What is Alibaba Health's EBITDA margin? | Alibaba Health's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of Alibaba Health? | Current EBITDA multiple of Alibaba Health is 36.0x. |
| What is the current FCF of Alibaba Health? | Alibaba Health's last 12 months FCF is $191M. |
| What is Alibaba Health's FCF margin? | Alibaba Health's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Alibaba Health? | Current FCF multiple of Alibaba Health is 46.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
